Karina Lahnakoski

Karina is Optimi’s Director of Quality and Commercial Strategies focussing on commercial scale up, GACP and GMP processes for Optimi’s drug pipeline serving the international, legal psychedelic market. Karina brings 20 years industry experience and over 10 years of consulting experience in regulated industries: cannabis, biopharma, pharmaceutical and medical devices. In industry Karina held roles focused in quality assurance, new product development/commercialization, scale up and regulatory strategy. In consulting Karina focussed on supporting regulated industries with governance, modernization, operational transformation and resilience initiatives. Prior to Optimi, Karina held various roles including as Partner in Deloitte’s Risk Advisory Practice, VP of Quality and Regulatory at CCI (Canada’s first cannabis consultancy firm, later acquired by Deloitte) and Director of Quality at Dalton Pharma Services – a CDMO with early phase and commercial products including controlled dugs and substances. Karina holds a Master’s in Business Administration (MBA) from York University and B.Sc in Biochemistry from University of Guelph.